CRIS Current Research Information System

LOLLI, CRISTIAN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.216
AS - Asia 1.742
EU - Europa 1.507
AF - Africa 146
SA - Sud America 117
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.190
SG - Singapore 725
CN - Cina 476
IT - Italia 384
GB - Regno Unito 249
VN - Vietnam 205
DE - Germania 182
SE - Svezia 179
HK - Hong Kong 158
BR - Brasile 88
IN - India 77
CH - Svizzera 69
IE - Irlanda 68
NL - Olanda 65
FR - Francia 64
RU - Federazione Russa 61
TG - Togo 48
FI - Finlandia 45
KR - Corea 39
CI - Costa d'Avorio 30
UA - Ucraina 30
SC - Seychelles 27
ZA - Sudafrica 24
BG - Bulgaria 23
AT - Austria 22
EE - Estonia 21
BE - Belgio 16
AR - Argentina 13
CA - Canada 12
ID - Indonesia 12
JP - Giappone 12
NG - Nigeria 10
JO - Giordania 9
PL - Polonia 9
CL - Cile 7
ES - Italia 7
IR - Iran 7
MX - Messico 6
CO - Colombia 5
GR - Grecia 5
BD - Bangladesh 4
NI - Nicaragua 4
TH - Thailandia 4
EG - Egitto 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
IQ - Iraq 2
LT - Lituania 2
MY - Malesia 2
PE - Perù 2
PH - Filippine 2
TR - Turchia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
IL - Israele 1
LU - Lussemburgo 1
MA - Marocco 1
MG - Madagascar 1
NO - Norvegia 1
PT - Portogallo 1
TN - Tunisia 1
TW - Taiwan 1
TZ - Tanzania 1
UZ - Uzbekistan 1
Totale 5.731
Salva come PNG Salva come JPEG
Città #
Singapore 526
Ashburn 323
Chandler 277
Southend 223
Fairfield 174
Hong Kong 156
Santa Clara 105
Wilmington 97
Hefei 94
Houston 79
Princeton 72
Beijing 70
Dublin 67
Bern 65
Woodbridge 65
Seattle 64
Bologna 61
Dong Ket 60
Cambridge 58
Ann Arbor 57
Boardman 51
New York 50
Lomé 48
Ho Chi Minh City 40
Seoul 39
Helsinki 38
Rome 34
Los Angeles 32
Abidjan 30
Turin 29
Hanoi 28
Nanjing 28
Buffalo 25
Milan 23
Sofia 23
Frankfurt am Main 22
Padova 22
Westminster 22
Berlin 21
Redmond 19
Munich 18
Redondo Beach 18
Dallas 17
Jinan 17
Brussels 16
San Diego 16
Vienna 13
Düsseldorf 11
Tokyo 11
Zhengzhou 11
Falls Church 10
Jiaxing 10
Amman 9
Des Moines 9
Fort Worth 9
Jakarta 9
Shanghai 9
Abeokuta 8
Changsha 8
Falkenstein 8
London 8
Norwalk 8
Prineville 8
Ravenna 8
São Paulo 8
Bengaluru 7
Dearborn 7
Hebei 7
Jacksonville 7
Medford 7
Nuremberg 7
San Francisco 7
Shenyang 7
Bremen 6
Guangzhou 6
Montescudo 6
Phoenix 6
Torino 6
Toronto 6
Foshan 5
Hangzhou 5
Lanzhou 5
Lauterbourg 5
Nanchang 5
Orem 5
Saint Petersburg 5
Warsaw 5
Yubileyny 5
Bangkok 4
Bari 4
Castel Maggiore 4
Fuzhou 4
Haiphong 4
Hyderabad 4
Lappeenranta 4
Managua 4
Mülheim 4
Rio de Janeiro 4
Rolo 4
Shenzhen 4
Totale 3.779
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 400
A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. 241
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 187
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. 185
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. 173
Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. 173
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 171
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). 170
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 161
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 159
Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. 156
MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype. 155
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib 151
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 150
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. 144
Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. 138
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma 133
Integrative analysis of gene expression profiling and high-resolution genomic copy number in gastrointestinal stromal tumor (GIST). 133
Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients 131
Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) 128
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 123
SDHA and SDHB mutations in KIT/PDGFRA WT gastrointestinal stromal tumors 123
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors 123
CRITICAL ANALYSIS ON MANAGEMENT OF GIST PATIENTS WITH EVENT TREE MODEL 122
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 118
The potential role of IGF1r in young adult patients with gastroinetstinal stromal tumor (GIST). 112
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 111
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 111
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 109
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment 103
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients 101
Plasma androgen receptor in prostate cancer 91
Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. 90
null 90
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 80
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 79
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 77
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 67
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 54
CAR-T cell therapy: A potential new strategy against prostate cancer 53
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 47
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 43
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 41
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 39
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 38
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 38
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 37
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 35
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics 34
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 33
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 33
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 29
Psychosocial issues in long-term survivors of testicular cancer 27
Totale 5.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021245 0 0 0 0 0 27 7 23 39 24 12 113
2021/2022704 59 10 24 49 58 27 40 43 28 66 181 119
2022/2023949 85 158 46 133 47 90 18 47 153 22 62 88
2023/2024303 34 38 22 33 15 72 6 16 24 9 19 15
2024/20251.340 79 174 137 120 196 80 58 66 23 96 51 260
2025/20261.307 237 231 222 186 374 57 0 0 0 0 0 0
Totale 5.850